Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ProQR Therapeutics (PRQR) EBITDA Margin (2021 - 2025)

ProQR Therapeutics' EBITDA Margin history spans 5 years, with the latest figure at 194.05% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 4001.0% to 194.05% in Q4 2025 year-over-year; TTM through Dec 2025 was 129.86%, a 9681.0% decrease, with the full-year FY2025 number at 256.15%, down 10957.0% from a year prior.
  • EBITDA Margin hit 194.05% in Q4 2025 for ProQR Therapeutics, down from 382.69% in the prior quarter.
  • Over the last five years, EBITDA Margin for PRQR hit a ceiling of 7565.69% in Q4 2021 and a floor of 6540.74% in Q2 2021.
  • Historically, EBITDA Margin has averaged 65.81% across 5 years, with a median of 167.8% in 2024.
  • The widest YoY moves for EBITDA Margin: up 791644bps in 2022, down -929625bps in 2022.
  • Tracing PRQR's EBITDA Margin over 5 years: stood at 7565.69% in 2021, then tumbled by -123bps to 1730.56% in 2022, then surged by 89bps to 190.86% in 2023, then fell by -23bps to 234.06% in 2024, then increased by 17bps to 194.05% in 2025.
  • Business Quant data shows EBITDA Margin for PRQR at 194.05% in Q4 2025, 382.69% in Q3 2025, and 336.94% in Q2 2025.